Heparin-induced thrombocytopenia cost-effectiveness of therapy

Revision as of 02:21, 31 July 2017 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy

CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy

Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news

Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]

Overview

Cost-Effectiveness of Therapy

The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.[1] Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. [1]

Characteristic/Parameter Argatroban Bivalirudin Fondaparinux
Cost of administration $411.43 $411.43 $25.40
Average wholesale price $1194.65 (1 vial of 250mg) $753.07 (1 vial of 250mg) $220.34 (1 syringe of 7.5mg) Total cost for 9 days of therapy $1326 $1562 $164


References

  1. 1.0 1.1 Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y; et al. (2016). "Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States". Blood. 128 (26): 3043–3051. doi:10.1182/blood-2016-07-728030. PMID PMID27793877 Check |pmid= value (help).